Cryoport, Inc. (CYRX)
| Market Cap | 663.80M +130.9% |
| Revenue (ttm) | 182.94M +14.0% |
| Net Income | 71.74M |
| EPS | 1.43 |
| Shares Out | 50.40M |
| PE Ratio | 9.19 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 720,977 |
| Open | 13.50 |
| Previous Close | 13.60 |
| Day's Range | 12.93 - 13.79 |
| 52-Week Range | 5.31 - 13.79 |
| Beta | 1.75 |
| Analysts | Strong Buy |
| Price Target | 14.44 (+9.64%) |
| Earnings Date | May 4, 2026 |
About CYRX
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company’s Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The comp... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CYRX stock is "Strong Buy." The 12-month stock price target is $14.44, which is an increase of 9.64% from the latest price.
News
Cryoport price target raised to $15 from $13 at Needham
Needham raised the firm’s price target on Cryoport (CYRX) to $15 from $13 and keeps a Buy rating on the shares.
Cryoport price target raised to $17 from $15 at BTIG
BTIG raised the firm’s price target on Cryoport (CYRX) to $17 from $15 and keeps a Buy rating on the shares. The firm is citing the company’s Q1 earnings beat…
Cryoport price target raised to $12 from $11 at Guggenheim
Guggenheim analyst Subbu Nambi raised the firm’s price target on Cryoport (CYRX) to $12 from $11 and keeps a Buy rating on the shares. After what the firm calls “a…
Cryoport Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 16% year-over-year to $47.8M, with strong double-digit gains across both Life Sciences Services and Products. Full-year guidance was raised to $192–$196M, and positive adjusted EBITDA is expected in the second half, driven by robust demand and operational improvements.
Cryoport reports Q1 EPS (25c), consensus (19c)
Reports Q1 revenue $47.8M, consensus $44.86M. Jerrell Shelton, CEO of Cryoport (CYRX), commented, “Cryoport delivered a strong start to 2026 with first-quarter revenue of $47.8 million, up 16% year-ov...
Cryoport Reports First Quarter 2026 Financial Results
First quarter revenue grew 16% year-over-year to $47.8 million Commercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued expansion in approved CGT pr...
Cryoport to Report First Quarter 2026 Financial Results on May 4, 2026
NASHVILLE, Tenn., April 20, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for ...
Craig-Hallum bullish on Cryoport, initiates with a Buy
As previously reported, Craig-Hallum initiated coverage of Cryoport (CYRX) with a Buy rating and $15 price target CryoPort is a specialized logistics provider serving the C> market. The firm believe...
Cryoport initiated with a Buy at Craig-Hallum
Craig-Hallum initiated coverage of Cryoport (CYRX) with a Buy rating and $15 price target
Cryoport Earnings Call Transcript: Q4 2025
Full year 2025 revenue exceeded guidance at $176.2M, driven by strong growth in commercial cell and gene therapy and life sciences services. 2026 guidance targets $190–$194M revenue and positive adjusted EBITDA in the second half, with continued innovation and global expansion supporting future growth.
Cryoport reports Q4 EPS (27c), consensus (21c)
Reports Q4 revenue $45.45M, consensus $42.92M. Jerrell Shelton, CEO of Cryoport (CYRX), commented, “2025 was a year of strong progress for Cryoport. We delivered full-year revenue of $176.2M, exceedin...
Cryoport sees FY26 revenue $190.0M-$194.0M, consensus $189.5M
16:11 EST Cryoport (CYRX) sees FY26 revenue $190.0M-$194.0M, consensus $189.5M
Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results
FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidance Life Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServic...
Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
NASHVILLE, Tenn., Feb. 17, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sci...
Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series
Self-Sustaining Fusion® 800 Series Cryogenic Freezer Delivers High-Capacity Storage, Flexibility, and Cost Benefits in Limited Space Environments NASHVILLE, Tenn., Feb. 11, 2026 /PRNewswire/ -- Cryop...
Cryoport Systems Wins 2025 BioTech Breakthrough Award For “BioServices Innovation of the Year”
Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around th...
Cryoport price target raised to $12.50 from $11 at UBS
UBS raised the firm’s price target on Cryoport (CYRX) to $12.50 from $11 and keeps a Buy rating on the shares.
Cryoport Earnings Call Transcript: Q3 2025
Double-digit revenue growth continued in both core segments, with commercial cell and gene therapy revenue up 36% year-over-year. Updated 2025 revenue guidance to $170–$174 million, targeting positive adjusted EBITDA by year-end, and significant operating leverage expected in 2026–2027.
Cryoport reports Q3 EPS (18c), consensus (19c)
Reports Q3 revenue $44.2M, consensus $41.22M. Jerrell Shelton, CEO of Cryoport (CYRX), commented, “Q3 was another outstanding quarter for Cryoport with 15% year-over-year growth in revenue from contin...
Cryoport raises FY25 revenue view to $170.0M-$174.0M from $165M-$172M
Consensus is for FY25 revenue $171.2M.
Cryoport Reports Third Quarter 2025 Financial Results
Third quarter revenue increased 15% year-over-year to $44.2 million Commercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3 million Life Sciences Services revenue grew 16% year-ove...
Cryoport Continues to Set New Benchmarks for the Global Regenerative Medicine Supply Chain
First Global Supply Chain Solutions Company to Achieve ISO 21973 Certification, Ensuring Highest Transport Safety, Traceability, and Integrity Standards for Cell and Gene Therapies NASHVILLE, Tenn. , ...
Cryoport to Report Third Quarter 2025 Financial Results on November 4, 2025
NASHVILLE, Tenn. , Oct. 21, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, to...
MVE Biological Solutions, A Cryoport Company, Introduces Real-Time Integrated Condition Monitoring Systems For Cryogenic Dewars
Connected, Intelligent Condition Monitoring Assets that Safeguard Vital Life Science Materials Mark MVE's First Step in its Real-Time Integrated Systems Evolution NASHVILLE, Tenn. , Oct. 7, 2025 /PRNe...
Cryoport launches state-of-the art facility in Louvres, France
Cryoport (CYRX) announced the launch of its newest, state-of-the art facility in Louvres, France, through its subsidiary, Cryoport Systems. The facility, which is strategically located near the Paris ...